Answers are grounded in this paper and cite their sources.
Theoretical framework demonstrates interface-level thermal boundary layer disruption across clinical and wellness settings, suggesting improved control over therapeutic heat transfer.
ThermaFlow™ v2.0 presents an expanded scientific and engineering framework for interface-level control of heat transfer through active manipulation of thermal boundary-layer formation, persistence, residence, instability, shear, and spatial distribution. Version 2.0 extends the original ThermaFlow™ framework into clinical, wellness, rehabilitation, neonatal, perioperative, pressure-injury, athletic-recovery, and other human–environment thermal-interface contexts. Rather than treating bulk-medium temperature as the sole control variable, the framework examines the state of the body–medium interface itself, including near-surface thermal and hydrodynamic conditions, boundary-layer behavior, tangential shear, controlled interface instability, thermal dose, and independently regulated spatial zones. The publication develops mathematical and engineering descriptions of interface heat flux, effective heat-transfer coefficient, boundary-layer dynamics, residence time, shear, disturbance energy, spatial control, thermal dose, feedback-based regulation, perfusion-aware control, and multi-zone thermal actuation. Version 2.0 further develops experimentally testable research architectures for clinical and wellness applications. Proposed physiological and clinical effects are presented as research hypotheses and engineering propositions requiring independent experimental and prospective validation rather than as established therapeutic effects. The framework is associated with a family of seven U.S. provisional patent applications identified in the publication's Patent-Family Provenance section. Research status: This work is presented for scientific discussion, engineering evaluation, reproducibility, prior-art analysis, and further experimental investigation. Proposed physiological or clinical effects require independent experimental validation. No therapeutic efficacy is claimed. Patent Pending — Based on seven U.S. provisional patent applications identified in the publication. Version: 2.0Zenodo DOI: 10.5281/zenodo.22166731
No takes yet. Share an insight, caveat, or question.
Pavel Pushkin (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: